Literature DB >> 11177740

Adjuvant chemotherapy for colon cancer.

S K Kumar1, R M Goldberg.   

Abstract

Colon cancer remains the third most common cancer, and cause of cancer-related death in the United States. Greater public awareness and acceptance of screening programs have contributed significantly to increasingly earlier detection of colon cancer and decreased mortality. Advances made in the understanding of this disease, both in terms of its clinical behavior and molecular pathogenesis, have translated into major improvements in its therapy. Several large randomized trials during the last two decades have helped the oncology community forge a successful multi-modality treatment strategy against colon cancer. These studies have defined the role of adjuvant therapy for colon cancer after curative surgery. Despite all the advances, a large number of patients continue to succumb to this disease, and the search for better therapies is still necessary. In this article, we discuss the evolution and the current state of adjuvant chemotherapy in colon cancer and briefly review new developments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177740     DOI: 10.1007/s11912-001-0007-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  39 in total

1.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

Authors:  G Riethmüller; E Holz; G Schlimok; W Schmiegel; R Raab; K Höffken; R Gruber; I Funke; H Pichlmaier; H Hirche; P Buggisch; J Witte; R Pichlmayr
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.

Authors:  D Nitti; J Wils; T Sahmoud; D Curran; M L Couvreur; M Lise; H Rauschecker; J G dos Santos; W Stremmel; F Roelofsen
Journal:  Eur J Cancer       Date:  1997-07       Impact factor: 9.162

3.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.

Authors:  K C Halling; A J French; S K McDonnell; L J Burgart; D J Schaid; B J Peterson; L Moon-Tasson; M R Mahoney; D J Sargent; M J O'Connell; T E Witzig; G H Farr; R M Goldberg; S N Thibodeau
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

4.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

Authors:  M J O'Connell; J A Mailliard; M J Kahn; J S Macdonald; D G Haller; R J Mayer; H S Wieand
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

5.  Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer.

Authors:  P H Sugarbaker; F J Gianola; J C Speyer; R Wesley; I Barofsky; C E Meyers
Journal:  Surgery       Date:  1985-09       Impact factor: 3.982

6.  US pivotal studies of irinotecan in colorectal carcinoma.

Authors:  H C Pitot
Journal:  Oncology (Williston Park)       Date:  1998-08       Impact factor: 2.990

7.  Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.

Authors:  N Wolmark; B Fisher; H Rockette; C Redmond; D L Wickerham; E R Fisher; J Jones; A Glass; H Lerner; W Lawrence
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

8.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

Authors:  N Wolmark; H Rockette; B Fisher; D L Wickerham; C Redmond; E R Fisher; J Jones; E P Mamounas; L Ore; N J Petrelli
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

9.  Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.

Authors:  R W Beart; C G Moertel; H S Wieand; J E Leigh; H E Windschitl; J A van Heerden; R J Fitzgibbons; B G Wolff
Journal:  Arch Surg       Date:  1990-07

10.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.

Authors:  I Taylor; D Machin; M Mullee; G Trotter; T Cooke; C West
Journal:  Br J Surg       Date:  1985-05       Impact factor: 6.939

View more
  2 in total

1.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

Review 2.  Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.

Authors:  Tess M E Derksen; Martijn J L Bours; Floortje Mols; Matty P Weijenberg
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.